In a subsequent phase 2 trial following autologous SCT, vaccination significantly increased CD4 and CD8 myeloma-specific T cells, with a CR rate of 47% and a 2-year PFS of 57% (144). This evidence concerns the gene CD4 and plasma cell myeloma.